European Companies Search Engine
EU funding (€9,999,253): A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT Hor 1 Dec 2023 EU Research and Innovation programme "Horizon"
Overview
Text
A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy. The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem. To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process. Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
Funded Companies:
| Company name | Funding amount |
| F. Hoffmann-LA Roche AG | ? |
| Charite - Universitaetsmedizin Berlin | €166,730 |
| Collaborate Project Management GmbH | €233,423 |
| European Society FOR Blood AND Marrow Transplantation | €1,071,585 |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | €2,429,610 |
| Healthtree Foundation Inc. | €668,430 |
| Helmholtz-Zentrum Dresden-Rossendorf e. V. | €280,828 |
| Information Technology FOR Translational Medicine (Ittm) SA | €632,384 |
| Institut Curie | €435,643 |
| Masarykova Univerzita | €564,221 |
| Myeloma Patients Europe Aisbl | €101,994 |
| Singleron Biotechnologies GmbH | €571,646 |
| Trinetx Oncology GmbH | €100,038 |
| Universitaet Leipzig | €1,715,059 |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | €157,404 |
| Universitair Medisch Centrum Utrecht | €465,986 |
| Universite de Namur | €404,274 |
Source: https://cordis.europa.eu/project/id/101136379
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: F. Hoffmann-La Roche Ltd., Basle, Switzerland.